A pilot open label, single dose trial of fenobam in adults with fragile X syndrome

OBJECTIVE: A pilot open label, single dose trial of fenobam, an mGluR5 antagonist, was conducted to provide an initial evaluation of safety and pharmacokinetics in adult males and females with fragile X syndrome (FXS). METHODS: Twelve subjects, recruited from two fragile X clinics, received a single...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Berry-Kravis, E, Hessl, D, Coffey, S, Hervey, C, Schneider, A, Yuhas, J, Hutchison, J, Snape, M, Tranfaglia, M, Nguyen, D V, Hagerman, R
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2009
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2658751/
https://ncbi.nlm.nih.gov/pubmed/19126569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jmg.2008.063701
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak